Ascendis Pharma A/S (ASND) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Ascendis Pharma A/S (ASND) closed at USD 227.00 on 2026-10-14, a change of +10.2 % over the past year, with a market capitalization of USD 14.91B.

Ascendis Pharma A/S recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Ascendis Pharma A/S key figures

Previous close

USD 227.00 (2026-10-14)

1-year change

+10.2 %

Market cap

USD 14.91B

Enterprise value

USD 14.52B

P/E ratio (trailing)

17.37

P/E ratio (forward)

21.04

EPS (trailing)

13.05

EPS (forward)

10.77

PEG ratio

n/a

Price to book

9.20

Revenue growth

114.7 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

3.87

Employees

1,189

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Ascendis Pharma A/S

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Ascendis Pharma A/S and compare it with other stocks.